Watch Live

Tweet TWEET

Health Care Initiatives, Clinical Data Presentations, Public Offerings, Contract Extensions and Publication of Pre-Clinical

   Health Care Initiatives, Clinical Data Presentations, Public Offerings,
Contract Extensions and Publication of Pre-Clinical Study - Research Report on
                Cigna, Arena, Synta, Healthways, and Catalyst

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, November 21, 2013

NEW YORK, November 21, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Cigna
Corp. (NYSE: CI), Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), Synta
Pharmaceuticals Corp. (NASDAQ: SNTA), Healthways Inc. (NASDAQ: HWAY), and
Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX). Today's readers may
access these reports free of charge - including full price targets, industry
analysis and analyst ratings - via the links below.

Cigna Corp. Research Report 

On November 18, 2013, Cigna Corp. (Cigna) announced that it has launched a
collaborative accountable care initiative with University Hospitals
Accountable Care Organization (UHACO). According to the Company, the program
aims to enhance care coordination and achieve the "triple aim" of improved
health, affordability and patient experience for Cigna customers. According to
the Company, the program will benefit approximately 10,000 people covered by a
Cigna health plan who receive care from the 1,500 primary care physicians and
specialists employed by University Hospitals (UH) in the Cleveland area. "We
need a patient-centered health care system that emphasizes prevention and
primary care and rewards physicians for quality of care and improved health
outcomes," said Julia Huggins, President of Cigna in Ohio. "A system that's
focused on value rather than volume will ultimately lead to a healthier
population and lower medical costs, which is good for individuals, families,
employers and doctors." The Full Research Report on Cigna Corp. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/7307_CI

Arena Pharmaceuticals, Inc. Research Report

On November 18, 2013, Arena Pharmaceuticals, Inc. (Arena) and Eisai Inc.
jointly announced the presentation of a new data analysis from the BELVIQ®
(lorcaserin HCl) Phase 3 clinical trial program at the American Heart
Association 2013 Scientific Sessions, to be held from November 16-20, 2013 in
Dallas, Texas. According to the Company, the abstract 'the Effects of
Lorcaserin on High-Sensitivity C-reactive Protein in Overweight and Obese
Patients: Data From Two Phase 3 Trials' will highlight the data presentation
on BELVIQ, which is believed to decrease food consumption and promote satiety
by selectively activating serotonin 2C receptors in the brain. The Full
Research Report on Arena Pharmaceuticals, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.analystscorner.com/r/full_research_report/6a95_ARNA

Synta Pharmaceuticals Corp. Research Report 

On November 18, 2013, Synta Pharmaceuticals Corp. (Synta) announced the
closing of its underwritten public offering of 16.1 million shares of common
stock, including 2.1 million shares sold in pursuant to the full exercise of
the underwriters' option to purchase additional shares, at a public offering
price of $3.75 per share. The Company informed that gross proceeds to Synta
from the offering are c.$60.4 million, before deducting the underwriting
discounts and commissions and estimated offering expenses payable by Synta.
The Company further informed that Jefferies LLC acted as the sole book-running
manager for the offering, while JMP Securities, Brean Capital, LLC and Roth
Capital Partners acted as co-managers for the same. The Full Research Report
on Synta Pharmaceuticals Corp. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/8ecc_SNTA

Healthways Inc. Research Report

On November 12, 2013, Healthways Inc. (Healthways) announced the extension of
its current contract offering its nationally acclaimed SilverSneakers® Fitness
Program to eligible Independence Blue Cross (IBC) members throughout
Pennsylvania, until 2014. "Independence Blue Cross is committed to exceeding
customers' expectations through the provision of innovative health and
wellness solutions like the SilverSneakers Fitness Program," said Ben R.
Leedle, Jr., Healthways' President and CEO. "By focusing on increased access
to quality health care and delivering value through its products and services,
IBC is demonstrating its commitment to their older adult members, with a
user-friendly, proven program that offers a unique combination of physical
fitness and essential social experiences." The Full Research Report on
Healthways Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/76fd_HWAY

Catalyst Pharmaceutical Partners Inc. Research Report 

On November 18, 2013, Catalyst Pharmaceuticals Partners, Inc. (Catalyst)
announced that the journal Epilepsia has accepted for publication of
preclinical proof-of-principle of CPP-115 efficacy in suppressing infantile
spasms (IS). According to the Catalyst, CPP-115 is a next-generation GABA
aminotransferase inhibitor being developed for the treatment of IS. "There is
a significant unmet medical need in this area, as parents of children who have
infantile spasms have a very difficult choice when it comes to treatment
options, as they must choose between drug-related risks and adequate
treatment," said Patrick J. McEnany, Chairman and CEO of Catalyst. The Company
further informed that it plans to initiate a Phase I multiple-dose ascending
study in the first half of 2014 to evaluate the safety and tolerability of
multiple ascending oral doses of CPP-115. The Full Research Report on Catalyst
Pharmaceutical Partners Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/a791_CPRX

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to making mistakes. If you notice any errors
    or omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://www.analystscorner.com/

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North
America)
 
Press spacebar to pause and continue. Press esc to stop.